生物技术公司Elicio Therapeutics宣布,其研究性疗法在临床试验中取得积极进展。数据显示,有两名患者在接受治疗后维持了完全缓解状态,持续时间均至少达到八个月。其中一位患者的完全缓解期更是超过了十三个月,展现了该疗法持久的潜在疗效。
生物技术公司Elicio Therapeutics宣布,其研究性疗法在临床试验中取得积极进展。数据显示,有两名患者在接受治疗后维持了完全缓解状态,持续时间均至少达到八个月。其中一位患者的完全缓解期更是超过了十三个月,展现了该疗法持久的潜在疗效。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.